Purchase this article with an account.
Seung-Young Yu, Eung Suk Kim, Bo Kwon Son, Hyung-Woo Kwak; Effects of Substance P on Mouse Model of Proliferative Vitreoretinopathy Induced by Dispase. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5365.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effects of substance P (SP) on mouse model of proliferative vitreoretinopathy (PVR) induced by dispase.
Total 12 C57BL/6J mice were conducted in this study. A PVR-like condition induced by intravitreal dispase injection. SP-treated group (6 of 12 C57BL/6J mice) were intravenously administered immediately and 24 h after intravitreal dispase injection and vehicle-treated group (6 of 12 C57BL/6J mice) were administered with sterile phosphate buffer saline (PBS). The effect of SP was evaluated by analyzing retinal structure via histologic analysis, cytokine related to systemic inflammation, and cell survival within retina of mice 1 week after injection.
At 1 week post injection, the vehicle-treated group showed developing of retinal folds, but the SP-treated group showed more intact retinal structure. Viable cells were increased in each retina layer in the SP-treated group compared to the PBS treated group. The ONL had 48.176 nuclei in the PBS-treated group, and 60.764 nuclei in the SP-treated group (PBS vs. SP groups, p<0.05). The INL had 19.294 nuclei in the PBS-treated group, and 22.470 nuclei in the SP treated group (PBS vs. SP groups, p<0.05). In addition, SP treatment alleviated the systemic inflammatory response. SP treatment caused a decrease in tumor necrosis factor-alpha (PBS-treated group: 82.200 ; SP-treated group: 45.828 pg/mL; PBS vs. SP groups, p<0.05) and an increase in interleukin-10 (PBS-treated group: 21.309 ; SP-treated group: 52.033 pg/mL ; PBS vs. SP groups, p<0.05).
The injection of SP suppressed the expression of inflammatory markers and disease progression in PVR model. Therefore, this study highlights the potential for the SP as a treatment to prevent conditions such as PVR.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only